Search:

Filter:

Post type:

Sort:

Case overview, USA v LFA Machines, 2026 –

September 28, 2026

In September 2026, DEA arrested three LFA Machine employees for allegedly selling pill presses to customers who they knew or had reasonable cause to believe would use them to manufacture illicit controlled substances.

Post-indictment restraining order, USA v LFA Machines, September 2026

September 28, 2026

United States District Court District of Arizona USA v LFA Machines, et al Post-indictment restraining order Filed September 2026 Read the document. (opens in new tab)

Application and supporting declaration for post-indictment restraining order, USA v LFA Machines, September 2026

September 28, 2026

United States District CourtDistrict of Arizona USA v LFA Machines, et al Government’s application for post-indictment restraining order Filed September 2026 Read the document and accompanying declaration. (opens in new tab) (opens in new tab)

Indictment, USA v LFA Machines, August 2026

September 28, 2026

United States District Court District of Arizona USA v LFA Machines, et al Indictment Filed August 2026 Read the document. (opens in new tab)

September 21, 2026: Pill press bill passes House as owners of LFA Machines arrested

September 24, 2026

Three senior employees of the pill press company have been arrested as the U.S. House unanimously passes the Stop Pills That Kill Act, which attempts to disrupt the pill press trade.

Statement on FDA’s Warning Letter to Empower Pharmacy for producing drug products in violation of federal law

September 23, 2026

“Don’t overlook the most consequential finding in this letter. The FDA flagged prescriber determinations that appeared verbatim across hundreds of patient records – like copy-pasted language, pre-loaded for selection, never actually written for an individual patient. The FDA made clear that approach does not meet the bar for prescribing a compounded drug, which must be tailored to the needs of an individual patient.
…
“The FDA must follow this letter with action – seizures and injunctions where warranted – and Congress should work quickly to close the policy gaps that have allowed this shadow drug supply to persist. Patients deserve medicines they can trust.”

September 16, 2026: Third Texas peptide compounder hit with recall

September 16, 2026

Centric Compounding received nine reports of adverse events related to the injections.

Compounded GLP-1 crisis: what patients and policymakers need to know

September 15, 2026

Telehealth companies and mass compounders are selling knockoff GLP-1s to patients who believe they’re getting the real thing. They aren’t.

September 8, 2026: Researchers say evidence that peptides are effective “is just not there”

September 9, 2026

A UCLA Health review of 565 studies on six popular unapproved peptides concluded that marketing claims about peptides are far ahead of the science.

Government’s Opposition to Defendant’s Motion to Suppress, USA v Rebecca Fadanelli January 2026

September 9, 2026

United States District Court District of Massachusetts USA v Rebecca Fadanelli Government’s opposition to defendant’s motion to suppress Filed January 2026 Read the document. (opens in new tab)